Savara (NASDAQ:SVRA) Trading Up 4.7% – What’s Next?

Savara Inc (NASDAQ:SVRA)’s stock price traded up 4.7% on Tuesday . The company traded as high as $4.30 and last traded at $4.26. 40,619 shares changed hands during trading, a decline of 97% from the average session volume of 1,197,658 shares. The stock had previously closed at $4.07.

Analyst Ratings Changes

A number of research analysts have recently issued reports on SVRA shares. Evercore ISI restated an “in-line” rating and issued a $5.00 price target (down from $7.00) on shares of Savara in a research report on Wednesday. JMP Securities restated a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research note on Tuesday, October 1st. Finally, HC Wainwright dropped their price target on Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $10.17.

Savara Trading Down 15.1 %

The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26. The firm’s 50 day simple moving average is $3.96 and its 200 day simple moving average is $4.22.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.11). Sell-side analysts predict that Savara Inc will post -0.44 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. CANADA LIFE ASSURANCE Co acquired a new position in shares of Savara during the 1st quarter valued at $35,000. Choreo LLC bought a new stake in Savara in the second quarter worth about $59,000. DRW Securities LLC acquired a new stake in Savara in the 2nd quarter valued at about $62,000. Principal Financial Group Inc. boosted its position in shares of Savara by 64.4% during the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after purchasing an additional 6,973 shares in the last quarter. Finally, Profund Advisors LLC acquired a new position in shares of Savara in the 2nd quarter worth approximately $105,000. 87.93% of the stock is currently owned by institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.